These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

592 related articles for article (PubMed ID: 36115807)

  • 1. Current and emerging immunotherapeutic approaches for biliary tract cancers.
    Yuan ZG; Zeng TM; Tao CJ
    Hepatobiliary Pancreat Dis Int; 2022 Oct; 21(5):440-449. PubMed ID: 36115807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomarkers for response to immunotherapy in hepatobiliary malignancies.
    Lin ZF; Qin LX; Chen JH
    Hepatobiliary Pancreat Dis Int; 2022 Oct; 21(5):413-419. PubMed ID: 35973935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current Role and Future Perspectives of Immunotherapy and Circulating Factors in Treatment of Biliary Tract Cancers.
    Conci S; Catalano G; Roman D; Zecchetto C; Lucin E; De Bellis M; Tripepi M; Guglielmi A; Milella M; Ruzzenente A
    Int J Med Sci; 2023; 20(7):858-869. PubMed ID: 37324191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evolving Role of Immunotherapy in Advanced Biliary Tract Cancers.
    Kang S; El-Rayes BF; Akce M
    Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The emerging role of immunotherapy in biliary tract cancer: a review of new evidence and predictive biomarkers.
    Giorgione R; Risaliti M; Bartolini I; Rossi G; Pillozzi S; Muiesan P; Taddei A; Antonuzzo L
    Immunotherapy; 2022 May; 14(7):567-576. PubMed ID: 35382560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted therapies in advanced biliary tract cancers-a narrative review.
    LaPelusa M; Heumann T; Goff L; Agarwal R
    Chin Clin Oncol; 2023 Apr; 12(2):14. PubMed ID: 36946186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapeutic Approaches to Biliary Cancer.
    Shah UA; Nandikolla AG; Rajdev L
    Curr Treat Options Oncol; 2017 Jul; 18(7):44. PubMed ID: 28660602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advances of immunotherapy for biliary tract cancer.
    Rizzo A; Ricci AD; Brandi G
    Expert Rev Gastroenterol Hepatol; 2021 May; 15(5):527-536. PubMed ID: 33215952
    [No Abstract]   [Full Text] [Related]  

  • 9. Immunotherapy in Biliary Tract Cancers: Current Standard-of-Care and Emerging Strategies.
    Lo JH; Agarwal R; Goff LW; Heumann TR
    Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer.
    Rizzo A; Ricci AD; Brandi G
    Expert Opin Investig Drugs; 2021 Apr; 30(4):343-350. PubMed ID: 33645367
    [No Abstract]   [Full Text] [Related]  

  • 11. Combination of AKT1 and CDH1 mutations predicts primary resistance to immunotherapy in dMMR/MSI-H gastrointestinal cancer.
    Wang Z; Zhang Q; Qi C; Bai Y; Zhao F; Chen H; Li Z; Wang X; Chen M; Gong J; Peng Z; Zhang X; Cai J; Chen S; Zhao X; Shen L; Li J
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35705314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The state of therapy modalities in clinic for biliary tract cancer.
    Chen W; Hu Z; Song J; Wu Y; Zhang B; Zhang L
    Front Biosci (Landmark Ed); 2022 Jun; 27(6):185. PubMed ID: 35748261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-L1, TMB, MSI, and Other Predictors of Response to Immune Checkpoint Inhibitors in Biliary Tract Cancer.
    Rizzo A; Ricci AD; Brandi G
    Cancers (Basel); 2021 Feb; 13(3):. PubMed ID: 33535621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune checkpoint inhibitors in luminal gastrointestinal malignancies: going beyond MSI-H/dMMR, TMB and PD-L1.
    Lefler DS; Snook AE; Bashir B
    Immunotherapy; 2022 Aug; 14(11):885-902. PubMed ID: 35694998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Death-Ligand 1 Blockade Responses.
    Yoon JG; Kim MH; Jang M; Kim H; Hwang HK; Kang CM; Lee WJ; Kang B; Lee CK; Lee MG; Chung HC; Choi HJ; Park YN
    Hepatology; 2021 Oct; 74(4):1914-1931. PubMed ID: 33884649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Application of immune checkpoint inhibitors and microsatellite instability in gastric cancer.
    Yan SY; Fan JG
    World J Gastroenterol; 2024 Jun; 30(21):2734-2739. PubMed ID: 38899328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy in MMR-d/MSI-H recurrent/metastatic endometrial cancer.
    Pacholczak-Madej R; Bartoletti M; Musacchio L; Püsküllüoglu M; Blecharz P; Lorusso D
    Expert Rev Anticancer Ther; 2024 Aug; 24(8):717-729. PubMed ID: 38863432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of Immune Checkpoint Inhibitors in Gastrointestinal Malignancies.
    Mazloom A; Ghalehsari N; Gazivoda V; Nimkar N; Paul S; Gregos P; Rateshwar J; Khan U
    J Clin Med; 2020 Aug; 9(8):. PubMed ID: 32781500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Next-generation sequencing-guided molecular-targeted therapy and immunotherapy for biliary tract cancers.
    Zhang W; Shi J; Wang Y; Zhou H; Zhang Z; Han Z; Li G; Yang B; Cao G; Ke Y; Zhang T; Song T; QiangLi
    Cancer Immunol Immunother; 2021 Apr; 70(4):1001-1014. PubMed ID: 33095329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of immunotherapy in advanced and recurrent MMR deficient and proficient endometrial carcinoma.
    Di Dio C; Bogani G; Di Donato V; Cuccu I; Muzii L; Musacchio L; Scambia G; Lorusso D
    Gynecol Oncol; 2023 Feb; 169():27-33. PubMed ID: 36493574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.